Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chiron/Searle Tifacogin Will Begin Two-Year, 1,500 Patient Trial In Sepsis

Executive Summary

Chiron will initiate a pivotal, 1,500 patient trial of tifacogin in sepsis in the first half of the year, Chiron Chairman & CEO Sean Lance said during a Feb. 8 conference call announcing the company's sales and earnings for 1999.

You may also be interested in...



Pharmacia takes a shot at sepsis

"You will be hearing more...in the fall" about the potential sepsis agent tifacogin, Pharmacia CFO Chris Coughlin tells the Goldman Sachs conference June 14. "It is a high risk area" and "we tend to be conservative and not try to tout these things too early," Coughlin says. The recombinant protein tissue factor pathway inhibitor, being developed in collaboration with Chiron, entered Phase III in mid-2000; interim data from the two-year, 1,500-patient trial will be analyzed around year-end (1"The Pink Sheet" Feb. 14, 2000, p. 33)

Pharmacia takes a shot at sepsis

"You will be hearing more...in the fall" about the potential sepsis agent tifacogin, Pharmacia CFO Chris Coughlin tells the Goldman Sachs conference June 14. "It is a high risk area" and "we tend to be conservative and not try to tout these things too early," Coughlin says. The recombinant protein tissue factor pathway inhibitor, being developed in collaboration with Chiron, entered Phase III in mid-2000; interim data from the two-year, 1,500-patient trial will be analyzed around year-end (1"The Pink Sheet" Feb. 14, 2000, p. 33)

Detrol Sales Potential Could Be $1 Bil. With Once-Daily Indication, P&U Says

The sales potential of Pharmacia & Upjohn's overactive bladder treatment Detrol (tolterodine) could be up to half a billion dollars greater than previous projections, pending approval of a once-daily formulation.

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel